Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05540275 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Tislelizumab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for Bevacizumab Refractory Recurrent Glioblastoma

StatusNot Yet Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated October 6, 2023 (before its estimated December 2024 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date: Nov 1, 2022 to Oct 5, 2023
    • Interventions: Sintilimab plus Bevacizumab (Drug) to Tislelizumab plus Bevacizumab (Drug)
    • Study title revised
    v3
  2. Primary completion date: Dec 2023 to Dec 2024v2 Show 4 more changesShow less
    • Start date: Jan 1, 2020 to Nov 1, 2022
    • Trial status: Recruiting to Not Yet Recruiting
    • Interventions: Tislelizumab plus Bevacizumab (Drug) to Sintilimab plus Bevacizumab (Drug)
    • Site details revised
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate the clinical efficacy and safety of Tislelizumab (one anti-PD-1 antibody same as nivolumab approved in China) in combination with bevacizumab in patients with recurrent or progressive glioblastoma (GBM) who have progressed on bevacizumab with or without PTEN or TERT gene mutations.
Trial Details
NCT Number NCT05540275
Lead Sponsor Henan Provincial People's Hospital
Conditions
(from sponsor)		 Recurrent Glioblastoma
Related terms Glioblastoma
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov